Meda expands collaboration with the Indian pharmaceutical company Cipla

Meda is broadening its collaboration with the Indian pharmaceutical company
Cipla, thereby expanding its exclusive rights to Dymista and future product
development. Through the extended partnership, Meda now have full coverage in
all growth markets in Latin- and South America, Middle East and Africa and Asia,
including more than 120 new markets.

Meda and Cipla will cooperate on product development of Dymista. Cipla will be
responsible for formulation, while Meda will be responsible for clinical
development, registration, marketing and sales. The companies will also
collaborate on future production of Dymista and any new products developed.

“Through this expanded partnership, we secure opportunities for global
commercialization of Dymista and optimize future product development,” says
Anders Lönner, Meda’s CEO. “Not least, we see great potential in several
priority growth markets such as China.”

About Dymista

Dymista is a novel nasal treatment of allergic rhinitis. The efficacy and safety
of Dymista has been documented in several studies with more than 4,000 patients,
including a long-term safety study with more than 600 patients. Dymista has
consistently shown faster and more complete symptom relief than standard
treatment in the US. Dymista was approved in the US in May 2012 and in Europe in
January 2013.
For further inquiries, please contact:

Paula Treutiger, Investor Relations                         ph: 46 733-666 599
MEDA AB (publ) is a leading international specialty pharma company. Meda’s
products are sold in more than 120 countries worldwide and the company is
represented by its own organizations in over 55 countries. The Meda share is
listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm.
Find out more, visit www.meda.se.

Forward-looking Statements
This press release is not an offer to sell or a solicitation to buy shares in
Meda. This press release also contains certain forward-looking statements with
respect to certain future events and Meda’s potential financial performance.
These forward-looking statements can be identified by the fact that they do not
relate only to historical or current facts, and may sometimes include words such
as “may”, “will”, “seek”, “anticipate”, “expect”, “estimate”, “intend”, “plan”,
“forecast”, “believe” or other words of similar meaning. These forward looking
statements reflect the current expectations on future events of the management
at the time such statements are made, but are made subject to a number of risks
and uncertainties. In the event such risks or uncertainties materialize, Meda’s
results could be materially affected. The risks and uncertainties include, but
are not limited to, risks associated with the inherent uncertainty of
pharmaceutical research and product development, manufacturing and
commercialization, the impact of competitive products, patents, legal
challenges, government regulation and approval, Meda’s ability to secure new
products for commercialization and/or development and other risks and
uncertainties detailed from time to time in Meda AB’s interim or annual reports,
prospectuses or press releases. Listeners and readers are cautioned that no
forward-looking statement is a guarantee of future performance and that actual
result could differ materially from those contained in the forward-looking
statements. Meda does not intend, nor undertakes, to update any such forward
looking statements.